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The Declaration of Helsinkiand other national and inter-national regulations oblige
Institutional Review Boards (IRBs)
to weigh the risks of medical
research against its benefits, and to
assess the ratio between the two. In
the Netherlands, the Medical
Research Involving Human Subjects
Act (WMO) states that a review
committee may only approve a
research study when “it is reasonable
to expect that the risk to and burden
for the subject will be in proportion
to the potential value of the
research.”1 In order for a study to be
approved, this risk-benefit ratio
must, in the IRB’s opinion, be
“favorable,” “in balance,” or “pro-
portional.” This assumes that IRBs
are sufficiently aware of which risks
the medical research community and
society, in general, find acceptable in
relation to which benefits. The
extent to which this assumption is
justified in practice is open to ques-
tion, especially considering the vague
description of this requirement in the
various regulations.
The requirement for a favorable
risk-benefit ratio further presupposes
that IRBs know what is important to
research participants with respect to
their protection. Whether this
assumption is justified is also
unknown. For example, there are
indications that patients’ experiences
of recruitment to early phase cancer
trials and their perceptions of the
informed consent process reflect a
lack of understanding of the trial in
which they are taking part.2 This
may be due, in part to vagueness,
inconsistency, and overstatement of
benefit in the consent forms for these
trials.3
The absence of clear criteria for
assessing the risk-benefit ratio has
been identified as a weak link in the
IRB review process.4 Previous studies
have indicated that IRB members
find risk-benefit ratio assessments to
be one of the most difficult tasks
involved in reviewing research proto-
cols.5 For example, van Luijn et al.,
found that phase II cancer protocols
provide too little information relat-
ing to the evaluation of cost-benefit
and scientific issues; that IRB mem-
bers felt less than fully competent in
carrying out such evaluations; that
only a small minority of IRB mem-
bers weigh risks and benefits against
each other in a systematic way,
rather than intuitively; and that one-
third of IRB members did not deter-
mine the risk-benefit ratio them-
selves, but rather preferred to leave
that to the individuals being recruit-
ed for the studies.6 The results of
another study indicated that the final
judgment by IRB members on a
trial’s ethical acceptability was signif-
icantly correlated with the assess-
ment of the protocol’s risk-benefit
ratio.7
Little is known, however, about
the kinds of difficulties IRB members
experience when making risk-benefit
assessments, whether they need assis-
tance in making these assessments,
and whether they think patients
should participate in the IRB’s
assessment of risks and benefits. In
this article, we report on a study that
sought to determine which aspects of
the risk-benefit ratio assessment of
phase II and phase III cancer clinical
trials individual IRB members find
the most difficult, whether they
require more information and educa-
tion in making such assessments,
how the process can be improved,
and whether the participation of
patients is viewed as a means of
improving the quality of the assess-
ments.8
Study Methods
The IRBs of six Dutch academichospitals and two specialized
cancer centers were asked by mail to
participate in the study. We did not
select non-academic hospitals
because they do not evaluate suffi-
cient numbers of cancer clinical trials
to be appropriate candidates for
such a study. Six of the eight IRBs
agreed to participate, including the
academic hospitals of the universities
of Utrecht, Rotterdam, and Leiden,
the Vrije Universiteit in Amsterdam,
the Netherlands Cancer
Institute/Antoni van Leeuwenhoek
Hospital in Amsterdam, and the
Daniel den Hoed Cancer Center in
Rotterdam. All members of these
IRBs (N = 64) were invited to take
part in the study, of whom 52 agreed
to do so. One IRB member of the
IRB of a fifth Dutch academic hospi-
tal also agreed to participate. The
primary reason for not participating
was the time-consuming nature of
the research. The participating IRB
members included medical specialists
(41%), family physicians (8%), nurs-
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es (15%), and individuals from other
disciplines (36%), including four
pharmacists, two ethicists, two social
scientists, one statistician, and one
attorney, among others. The age of
the participants ranged from 28 to
69 years and the majority of respon-
dents (64%) were male. Nine per-
cent had served on the IRB for less
than one year, 47% for between one
and four years, and 44% for four
years or longer.
We conducted semi-structured
interviews using a combination of
open- and closed-ended questions
that focused on the most difficult
aspects in assessing the risk-benefit
ratio of phase II and phase III cancer
clinical trial protocols; the perceived
need for additional information and
education in making this assessment;
suggestions for improving the risk-
benefit assessment; and the desirabil-
ity of having patients participate in
the IRBs’ assessment of a trial’s risks
and benefits. The interview schedule
was developed on the basis of the lit-
erature9 and had been previously
pilot tested among five IRB members
or former IRB members. The first
author performed the interviews at
the IRB members’ place of work. On
average, the interview took approxi-
mately one hour to complete.
The interviews included two
open-ended questions concerning the
most difficult aspects of assessing the
risks and benefits of phase II and
phase III cancer protocols and three
open-ended questions concerning the
need for more information and edu-
cation, and suggestions for improv-
ing the risk-benefit assessment
process for these types of protocols.
One closed-ended question con-
cerned the desirability of having
patients participate in the IRBs’
assessment of the risk-benefit ratio
(Table 1). Responses were scored on
a 4-point Likert scale from 1 (very
desirable) to 4 (not desirable at all).
Respondents were asked to describe
the reasons underlying the responses
that they provided to the question.
Open-ended questions were
organized into categories and are
reported as percentages. The cate-
gories were not always mutually
exclusive, as respondents could, for
example, mention more than one
difficult aspect of the assessment of
the risk-benefit ratio (Table 2), type
of support needed (Table 3), or sug-
gestion for improving the IRB’s risk-
benefit ratio assessments (Table 4).
Responses are illustrated in the text
with salient statements made by IRB
members.
Descriptive statistics were calcu-
lated for responses to the closed-
ended question. Chi-square statistics
were used to test whether the back-
ground characteristics of the IRB
members (e.g., age, gender, profes-
sional background, years of experi-
ence on IRBs) were associated signif-
icantly with perceived need for infor-
mation and training, and attitudes
towards patient membership on an
IRB.
Results
As reported in Table 2, makingrisk-benefit ratio decisions with-
out clear criteria and in the face of
uncertainty with regard to patient
benefits and study rationale were
Table 1. Interview Questions
Would you like more information and education in assessing the RBR of protocols? 
What kind of information and education would you like? 
Do you have any suggestions that would make the RBR assessment process easier
for you? 
Do you believe that it is desirable for patients (who have experience as research
subjects) to participate in an IRB?
Table 2. Opinions of IRB Members Concerning the Most Difficult 
Aspects of Assessing the Risk-Benefit Ratio of Phase II and Phase III 
Cancer Trials (n=53)
Phase II    Phase III
Lack of criteria to assess the risk-benefit ratio 62% 39%
Uncertainty about the benefits to patients 41% 37%
and the study's rationale
Doing research/confronting patients with difficult 
choices in the face of necessary risks 15% 0% 
Gaining a view of all relevant factors 12% 2%
Withholding treatment because of placebo 0% 10% 
Various other aspects 21%a 27%b
a. e.g., No feedback on study results, therefore it remains unclear whether the estimation and evalua-
tion of risks and benefits was correct; communication with other IRB members about the RBR; the
researchers' reaction if the protocol is rejected
b. e.g., No feedback on study results; uncertainty about toxicity; the perhaps unrealistic hope that is
provided to patients by letting them participate in the study; 
Note: The percentages do not total 100% because more than one response could be given.
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perceived as the two most difficult
aspects of the process of assessing
the risk-benefit ratio for phase II and
III cancer trials. Specific issues men-
tioned by respondents during the
interview included difficulty in com-
paring risks with benefits, inade-
quate knowledge of the acceptability
of certain risks, and an inability to
imagine the impact of a failed clini-
cal trial-based treatment on the
patient/subjects.
Fifty-six percent of the IRB mem-
bers reported that they would like to
receive more information about and
education in assessing the risk-bene-
fit ratio of protocols. As indicated in
Table 3, approximately half of the
respondents who expressed interest
in receiving more information or
training favored courses or seminars,
and one-third indicated a desire to
obtain feedback on trial results and
on the experiences of patient/subjects
who participate in trials. The
remaining IRB members (44%)
expressed no desire for additional
training or assistance in how to
assess the risk-benefit ratio of proto-
cols, as they believed that the IRB
meetings themselves provided suffi-
cient training opportunities and
sources of information.
As shown in Table 4, more than
half of the IRB members reported
wanting more information, particu-
larly relating to patients’ perceptions
of the risks and benefits involved
with clinical trials. Approximately
one-quarter of the respondents
reported that it would be helpful if
investigators provided IRB members
with their own assessment of a
study’s risk-benefit ratio. Additional
training and the use of a checklist in
order to review all of the major
issues involved in assessing a study’s
risk-benefit ratio were also men-
tioned as possibly helpful in facilitat-
ing the IRB’s review process.
The majority of respondents
(54%) opposed the idea of having
patients (who have experience as
research subjects) participate on the
IRB (Table 5). Those who rejected
this proposal did not believe that
patients had any specific contribu-
tion to make, were concerned that
open discussions would be ham-
pered, believed patients would make
judgments solely on the basis of their
own personal experiences, or felt
that participation on an IRB would
simply be too difficult or would
impose too great a burden on
patients. Still others believed that the
logistics would be difficult because
different patients would be needed
for different protocols, or that it
would be difficult to find a single
patient who could represent the
diverse population(s) of patients.
Twenty-three percent of the IRB
members considered it desirable to
have patients on IRBs, and the
remaining 23% expressed no opin-
ion. Most of those favoring patient
participation considered patients to
be “experiential experts” who could
inform other IRB members about
the meaning of risks and benefits.
Table 3. Type of Information and Education Desired by IRB Members in
Assessing the Risk-Benefit Ratio of Phase II and III Cancer 
Clinical Trials (n=30) a
Courses or seminars 52%
Feedback on patients’ trial experiences and trial results 32%
Reflection on past decisions/overview 
of new developments in oncology research 8%
Variousb 36%
Note: The percentages do not total 100% because more than one response could be provided. 
a. Only IRB members who said that they needed more knowledge and education answered this ques-
tion.
b. Including: risk-benefit assessment by researchers; methodological aspects; how to apply general
ethical concepts to particular protocols; guidelines about how to assess the RBR; feedback on indi-
vidual IRB performance; more training in legal matters and animal research; a list with important
things to think about for every member.
Table 4. IRB Members' Suggestions for Improving the Risk-Benefit
Assessment of Phase II and III Cancer Clinical Trials (n=53)
More knowledge available on trial experience/
risk-benefit perceptions of patients 56%
Risk-benefit assessments by researchers 26%
Additional training and checklists for IRB members 23%
More time for preparation and discussion/
contact with researchers 9%
Improvement of IRB discussions 7%
Various 28%
Note: The percentages do not total 100% because more than one suggestion could be given.
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Others believed that patients are bet-
ter able to evaluate the quality of
written patient information than
other IRB members.
Significantly fewer oncologists
believed that they could benefit from
more information and education
than did other professionals (18%
versus 62%; p < .05). No statistically
significant associations were found
between duration of IRB member-
ship, age or gender and the perceived
need for more information and edu-
cation. Relatively new IRB members
(those with four or fewer years of
experience on an IRB) were signifi-
cantly more likely to favor patient
participation on IRBs than were
members with more experience
(38% versus 4%; p = .02). Although
not statistically significant, fewer
physicians than other professionals
favored having patients as members
of IRBs (12% versus 35%). Finally,
significantly more female than male
IRB members were opposed to hav-
ing patients serve on IRBs (72% ver-
sus 44%; p = .02).
Discussion
The objective of this study was toobtain insight into the IRB
process of assessing the risk-benefit
ratio of phase II and III cancer clini-
cal trials as experienced by individ-
ual members of IRBs. We first
sought to identify the most difficult
aspects of the risk-benefit assessment
of phase II and III protocols. The
lack of criteria for assessing the risk-
benefit ratio, the uncertainty con-
cerning the benefits to patients, and
the study rationale were reported as
the most difficult aspects of the
assessment process. Other studies
have also found a lack of clear crite-
ria for evaluating a trial’s risk-benefit
ratio and IRB members’ lack of tech-
nical expertise necessary for weigh-
ing the risks and benefits against
each other to be major problems.10
Second, we investigated the needs
expressed by IRB members for more
information and education in assess-
ing the risk-benefit ratio of phase II
and III cancer protocols and their
suggestions for improving their own
assessments. Most respondents
reported that additional information
and education would be welcome.
Although courses are available for
IRB members in the Netherlands,
they are not mandatory and only a
small percentage of members attend
them.
The IRB members made a num-
ber of suggestions regarding possible
ways to improve the assessment of
the risk-benefit ratio of phase II and
III cancer protocols: receiving more
information about patients’ trial
experiences and risk-benefit percep-
tions; receiving researchers’ assess-
ment of the risk-benefit ratio; and
providing checklists and more train-
ing facilities for IRB members.
The findings of our study indicate
that IRBs know little about the per-
ceptions and experiences of patients
regarding the risks and benefits of
research participation. In addition,
the findings suggest a striking ten-
sion in IRB members’ apparent lack
of insight into the patient perspective
(i.e., the meaning of the risks and
benefits to patients) and their actual
task (protecting human subjects
against medical research that carries
too many risks). This also suggests
that, to be able to assess the risk-
benefit ratio of a study (i.e., to have
criteria for weighing risks and bene-
fits against each other), more knowl-
edge of the patients’ perspective is
needed. Such information may then
become part of a broad mix of fac-
tors that IRBs consider in assessing a
study’s risk-benefit ratio. When IRBs
know how patients have experienced
participation in trials comparable to
the study in question, it may be pos-
sible for IRB members to make a
comparison between their own per-
ceptions of risks and benefits and
those of the patients. IRBs can then
take the patients’ perspective—
beyond their own perceptions—into
consideration in order to improve
their assessment of the risk-benefit
ratio.
To determine whether their deci-
sion to approve a research protocol
is ethically justifiable, IRB members
must imagine the consequences of
their decision for patients.11
However, because it is impossible to
know how others will actually assess
these consequences, IRB members
can only make a rough estimate of
what their decisions will mean to
others.12 Risk-benefit assessments
depend on the relative importance of
the various factors to be weighed.
More insight is needed, therefore,
into the experiences, as well as the
values and goals, of patients if IRBs
are to be capable of determining the
importance of the factors and if risk-
benefit criteria are to be well
chosen.13 It is important to empha-
size, however, that the desire for
more information about the patients’
perspective should not be equated
with the common but mistaken view
that a study’s risk-benefit ratio is
acceptable if patients want to enroll.
The consent of the patient to become
a research subject is an essential, but
second moral requirement. The first
moral requirement for research is
that the risk-benefit ratio be assessed
and found acceptable, as has been
stated earlier. This is important to
recognize, because individual
Table 5.  IRB Members' Opinions About the Desirability of Having Patients
Participate on IRBs (n=53)
Patient participation on IRBs is desirable 23%
Patient participation on IRBs is not desirable 54%
Don't know/no opinion 23%
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patients are prepared to take signifi-
cant risks for small chances of bene-
fit. Thus we would emphasize that
the relevant patient role is as
patients/subjects, reflecting experi-
ences in research, but not necessarily
values. How patients view their
chances of benefit should not affect
the assessment of a study’s risk-bene-
fit ratio. The question whether per-
ceptions of risks and benefits by
potential trial participants (their
“values” or “preferences”) should
affect this assessment is a complicat-
ed one, because the assessment must
take place against the backdrop of
the alternatives to research participa-
tion that are available to patients; in
oncology, those may be dismal. This
issue should be one focus of future
empirical and conceptual research.
Third, we asked IRB members
about the desirability of having
patients participate in the review of
research protocols. Experiences with
patients reviewing AIDS protocols
have been positive.14 Others have
found that patients’ estimate of the
severity of certain risks differs con-
siderably from that of physicians
and nurses.15 Nevertheless, although
the respondents in our study indicat-
ed that their risk-benefit assessments
might be improved by having more
insight into the patients’ perspective
about research risks and benefits,
less than a quarter were in favor of
having patients participate on IRBs.
Of course, it makes a difference
whether the patients are potential
participants in the trials reviewed or
patients who have experience as
research subjects. These two patient
groups have very different things to
bring to the IRB table. There may be
considerable differences in the values
and feasibility of patients’ inclusion
on an IRB devoted to oncology
research in comparison to a general
medical IRB (since many IRB mem-
bers, lay or otherwise, have consid-
erable experience as patients).
Finally, we investigated the associ-
ation between IRB members’ back-
ground characteristics and their
views. Not surprisingly, fewer oncol-
ogists expressed the need for more
information and education in mak-
ing risk-benefit assessments than did
other professionals. Female IRB
members and those who had been
involved in IRBs for a longer period
of time tended to be less favorable
toward having patients participate
on IRBs, though it is unclear why
this is so. Although most nurses in
this study were female, there were
also many females from other pro-
fessions, and being a nurse had no
significant relationship with attitudes
towards patient participation on
IRBs.
The results must be interpreted in
light of certain limitations of the
study. First, the study did not distin-
guish among the various types of
phase II and III protocols (e.g.,
chemotherapy, radiotherapy, or sur-
gery). While there is no reason to
believe that this would have a signif-
icant impact on the findings, it could
be investigated in future studies. In
addition, respondents were not
asked to distinguish between proto-
cols arising from within their own
institutions and those from other
sources (either national or interna-
tional). Unfortunately, we could not
obtain systematic data on this matter
from the participating IRBs because
such information is not routinely
collected. Additional research is
needed, therefore, to determine
whether the perceived difficulties
associated with assessing the risk-
benefit ratio of protocols and the
need for information and education
vary significantly as a function of the
protocol’s origin (i.e., local versus
national or international; academic
versus industry)
We also note that the focus of our
research was on the individual mem-
bers of IRBs. The decisions made by
IRBs as a whole, and the discussions
that form the basis of such decisions,
are of a collective nature. Each IRB
member contributes to the decision-
making process from a unique pro-
fessional perspective, and the whole
is undoubtedly more than the sum of
its parts. A more dynamic, group-
oriented research approach is also
needed to obtain a more comprehen-
sive picture of the issues surrounding
risk-benefit assessments. In a future
paper, we will report the results of a
later stage of our research in which
such group dynamics were investi-
gated. At the same time, we would
emphasize that each IRB member
brings his or her own perspective to
such deliberations, and is expected
to be well prepared to participate
actively in the decision-making
process. Thus it is not inappropriate
to examine the attitudes and behav-
ior of individual IRB members.
The results of the current study
point to an intriguing paradox. On
the one hand, the absence of clear
criteria and the perceived uncertainty
about the benefits to patients and
the rationale for specific clinical tri-
als make assessment of the risk-ben-
efit ratio of phase II and III cancer
trials difficult—apparently so diffi-
cult that most IRB members would
like to receive additional information
and education in making such an
assessment (e.g., learning from past
experiences by providing feedback
on trial results or past decisions by
IRBs). Additionally, most IRB mem-
bers believe that additional insight
into the experiences and perceptions
of patients would help improve the
assessment process. On the other
hand, the majority of the surveyed
IRB members were opposed to hav-
ing patients participate on IRBs. We
believe that before systematically
excluding patients from IRB partici-
pation, empirical research is needed
to investigate the effects, both posi-
tive and negative, of having patient
participation on IRBs. Studies are
also needed about patients’ research
experiences and perceptions of the
risks and benefits of clinical trials.16
Both lines of research could con-
tribute meaningfully to better under-
standing of the risks and benefits of
research participation and to
improving the assessment of the risk-
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benefit ratio of phase II and III can-
cer clinical trials.
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